Spondyloarthritis Clinical Trial
— INTASAHOfficial title:
Intestinal Inflammation in Ankylosing Spondylitis Assessed by Fecal Calprotectin, Capsular Endoscopy and Colonoscopy and the Effects of Adalimumab on Mucosal Healing
Studies with intestinally asymptomatic patients with spondyloarthritis showed that approximately 1/3 had visible ulcers in the colon by scopic examinations and 2/3 had changes detectable by microscopy. Only those patients who improved in arthritis symptoms showed improvement in colonic changes. In these studies only colon and the terminal ileum was examined. Inflammation of the small intestine was not examined. Newer studies have shown an immunological link between Crohns disease and spondyloarthritis but not ulcerative colitis. The investigators wish to examine the small intestine in these patients before and after treatment, since they expect to find ulcers there linking spondyloarthritis to Crohns disease and healing after treatment.
Status | Completed |
Enrollment | 30 |
Est. completion date | March 2014 |
Est. primary completion date | June 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: - Patients (18 years and =45 years) with axial SpA according to the ASAS criteria - Active SpA assessed by physician. - Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) = 4. - Faecal calprotectin = 100mg/kg. - Negative pregnancy test (serum-HCG) for women of childbearing age before the start of the study. (Women not of childbearing age are defined as postmenopausal for at least 1 year or surgically sterilised (bilateral tubal ligation, bilateral oophorectomy or hysterectomy)). Women of childbearing age included in the study will be required to use contraception during the entire study period (i.e. one of the following: contraceptive pills, intrauterine device, depot injection of gestagen, subdermal implant, hormonal vaginal ring or transdermal patch). In addition, contraception must be used following any discontinuation of the study drug for a period of 150 days. - Ability and willingness to self-administer the subcutaneous injections or have a person available to administer the injections. - Ability and willingness to give written informed consent and meet the requirements of the study protocol. Exclusion Criteria: - Diagnosed inflammatory bowel disease or high risk of intestinal stricture (previous abdominal stricture, radiation of abdomen, major abdominal surgery). - Non steroid anti inflammatory Drugs (NSAID) ingestion less than 4 weeks before inclusion. - Psoriasis - Persons with latent Tuberculosis (TB)(positive Mantoux skin test (>10 mm), positive cultivation for mycobacteria in tissue samples and/or chest X-ray indicating TB) or other risk factors for activation of untreated latent TB. - Current or recurrent infections or serious infections requiring hospitalisation or treatment with intravenous antibiotics within the last 30 days or oral antibiotics within the last 14 days before inclusion. - Positive serology for Hepatitis B or C indicating active infection. - Medical history of positive HIV status (in case of suspicion control of HIV test). - Medical history of histoplasmosis or listeriosis. - Previous cancer or lymphoid proliferative disease except completely well-treated cutaneous squamous cell carcinoma, basal cell carcinoma or cervical dysplasia. - Previous diagnosis or signs of demyelinising diseases of the central nervous system (e.g. optic neuritis, disturbance of vision, disturbed gait/ataxia, facial paresis, apraxia). - Severe renal insufficiency (creatinine clearance < 35 ml/min - normogram).Affected hepatic function: Liver enzymes > 3 x above the normal limit. - Clinically significant drug or alcohol abuse in the last year or daily current alcohol consumption. - Diabetes, unstable ischemic heart disease, heart failure (NYHA III-IV), recent apoplexia cerebri (within 3 months), chronic leg ulcer and any other condition (e.g. indwelling catheter) which at the discretion of the investigator means that participation in the protocol would entail a risk for the person in question. - Anticoagulant treatment. - Pregnancy or breast-feeding. - Other clinically significant inflammatory rheumatologic diseases that cannot be related to spondyloarthritis - Current parvovirus B 19 infection. - Glucocorticosteroid treatment within the last 4 weeks (except nasal and inhalation steroids). - Contraindication to study drug. |
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
Denmark | Department of Rheumatology U, Aarhus Hospital | Aarhus | |
Denmark | Regional Hospital of Horsens, Department of Medicine | Horsens | |
Denmark | Regional Hospital of Randers, Department of Medicine | Randers | |
Denmark | Regional Hospital of Silkeborg | Silkeborg |
Lead Sponsor | Collaborator |
---|---|
Regionshospitalet Silkeborg | Abbott, Central Denmark Region, Given Imaging Ltd. |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change Lewis Score Index | Lewis' score describes the amount of inflammation seen optically by capsular endoscopy. Gralnek et al. devised and validated the Lewis score index, based on three endoscopic parameters: villous edema, ulcer and stenosis/stricture. Using these parameters, the authors established a score range of 8-4,800 points where: LS < 135 reflects normal mucosal appearances, LS 135-790 mild mucosal inflammatory change and an LS value =790 moderate to severe mucosal inflammatory changes. The patients had endoscopy performed at baseline and again after 20 weeks. The number of patients improving was compared to number of patients deteriorating |
20 weeks | No |
Primary | Change in Intestinal Inflammation Measured by Faecal Calprotectin | Feacal calprotectin is a protein and a marker of the degree of inflammation in the intestine, but not the site of inflammation. We measured the level calprotectin continuously in each of the patients. Difference was inferred by repeated measurement ANOVA |
Baseline to 52 weeks | No |
Secondary | Spondyloarthritis Consortium of Canada Score | Inflammation on MRI assessed by the Spondyloarthritis Consortium of Canada score and a Danish scoring method | one year | No |
Secondary | Assessment Group in Ankylosing Spondylitis (ASAS) Core Set for Clinical Practice | clinical measurements of inflammation in spondyloarthritis patients as described by the Assessment Group in Ankylosing Spondylitis (ASAS) | one year | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03564743 -
Description of Spondylarthritis and Validation of ASAS Criteria in West Indian Patients Seen in Consultation of Rheumatology.
|
||
Completed |
NCT01219257 -
Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy
|
||
Recruiting |
NCT05433168 -
Study Evaluating the Effectiveness of Shiatsu on Fatigue in Patients With Axial Spondyloarthritis
|
N/A | |
Terminated |
NCT03232580 -
99mTc-rhAnnexin V-128 in Diagnosis of Spondyloarthritis
|
Phase 2 | |
Recruiting |
NCT05039216 -
Biobank for Inflammatory Chronic Diseases and Osteoporosis
|
||
Completed |
NCT04483648 -
Cervical Stabilization Exercises in Patients With Spondyloarthritis
|
N/A | |
Recruiting |
NCT04602091 -
Observational Study in Patients Treated With JAK Inhibitors for Inflammatory Rheumatism (MAJIK)
|
||
Not yet recruiting |
NCT04077957 -
Treat-to-target Strategy in Ankylosing Spondylitis Using Etanercept and Conventional Synthetic DMARDs
|
Phase 4 | |
Recruiting |
NCT05290363 -
The Role of IL-23 in Chronic Inflammatory Disease: Exploring the Cellular and Molecular Targets of IL-23 Signaling in Peripheral and Axial Spondyloarthritis
|
N/A | |
Not yet recruiting |
NCT05006690 -
Telerehabilitation, Face-to-Face and Home-Based Spinal Stabilization Exercise Training in Patients With Spondyloarthritis
|
N/A | |
Completed |
NCT02998398 -
Evaluation of the Switch From the Original Infliximab to Its Biosimilar in Daily Practice at Cochin Hospital
|
||
Completed |
NCT02148640 -
The NOR-SWITCH Study
|
Phase 4 | |
Recruiting |
NCT04499001 -
Effect of Pharmaceutical Consultations Just Before Rheumatology Consultations on Improving Knowledge and Skills for Patients With Inflammatory Arthritis With Subcutaneous Biologic DMARDs
|
||
Completed |
NCT03253796 -
Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038)
|
Phase 4 | |
Active, not recruiting |
NCT04169373 -
A Study to Evaluate Efficacy and Safety of Upadacitinib in Adults With Axial Spondyloarthritis
|
Phase 3 | |
Recruiting |
NCT04292067 -
Characterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis
|
||
Completed |
NCT04946539 -
Value of Ultrasonographic Enthesitis Assessment in Spondyloarthritis
|
||
Recruiting |
NCT03983473 -
Identification of Fecal Microbiota Biomarkers of Spondyloarthritis in Patients Suffering From Crohn's Disease.
|
N/A | |
Terminated |
NCT03345355 -
MRI of Sacroiliac Joints: Evaluation of Accuracy of Dixon Sequences in the Diagnosis of Axial Spondyloarthritis
|
||
Completed |
NCT04360785 -
Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis
|
N/A |